key: cord-0959448-1yqtcgtx authors: Corso, Mariana Cristina M.; Soares, Victor J.; Amorim, Anna Maria P.; Cipolotti, Rosana; Magalhães, Isis Maria Q.; Lins, Mecneide M.; Forsait, Silvana; Silva, Luciana N.; de Sousa, Ana Virginia L.; Alves, Nádia G.; do Prado, Seila I.; Silva, Klerize Anecely S.; Carbone, Edna K.; Brumatti, Melina; Santiago, Pablo; Pereira, Kaline Maria M.O.; Carlesse, Fabianne A.M.C.; Aguiar, Marina G.; Marques, Rebeca F.; Rechenmacher, Ciliana; Daudt, Liane E.; Michalowski, Mariana B. title: SARS‐CoV‐2 in children with cancer in Brazil: Results of a multicenter national registry date: 2021-07-20 journal: Pediatr Blood Cancer DOI: 10.1002/pbc.29223 sha: effc5096fca769494fd32eb4f6f19d6ac29ee3d9 doc_id: 959448 cord_uid: 1yqtcgtx BACKGROUND: Strategies to mitigate the impact of COVID‐19 in special populations are complex and challenging. Few studies have addressed the impact of COVID‐19 on pediatric patients with cancer in low‐ and middle‐income countries. METHODS: Multicenter observational cohort study with prospective records and retrospective analyses starting in April 2020 in 21 pediatric oncology centers distributed throughout Brazil. Participants: Patients under 18 years of age who are infected by the SARS‐CoV‐2 virus (confirmed diagnosis through reverse transcriptase‐polymerase chain reaction [RT‐PCR]) while under treatment at pediatric oncology centers. The variables of interest included clinical symptoms, diagnostic and therapeutic measures. The repercussions of SARS‐CoV‐2 infection on cancer treatment and general prognosis were monitored. RESULTS: One hundred seventy‐nine patients were included (median age 6 [4–13] years, 58% male). Of these, 55.9% had acute leukemia and 34.1% had solid tumors. The presence of SARS‐CoV‐2 was diagnosed by RT‐PCR. Various laboratory markers were analyzed, but showed no correlation with outcome. Children with low or high BMI for age had lower overall survival (71.4% and 82.6%, respectively) than those with age‐appropriate BMI (92.7%) (p = .007). The severity of presentation at diagnosis was significantly associated with outcome (p < .001). Overall mortality in the presence of infection was 12.3% (n = 22). CONCLUSION: In children with cancer and COVID‐19, lower BMI was associated with worse prognosis. The mortality in this group of patients (12.3%) was significantly higher than that described in the pediatric population overall (∼1%). Results: One hundred seventy-nine patients were included (median age 6 [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] years, 58% male). Of these, 55.9% had acute leukemia and 34.1% had solid tumors. The presence of SARS-CoV-2 was diagnosed by RT-PCR. Various laboratory markers were analyzed, but showed no correlation with outcome. Children with low or high BMI for age had lower overall survival (71.4% and 82.6%, respectively) than those with ageappropriate BMI (92.7%) (p = .007). The severity of presentation at diagnosis was significantly associated with outcome (p < .001). Overall mortality in the presence of infection was 12.3% (n = 22). In children with cancer and COVID-19, lower BMI was associated with worse prognosis. The mortality in this group of patients (12.3%) was significantly higher than that described in the pediatric population overall (∼1%). In late 2019, a novel coronavirus was identified by Chinese scientists in Wuhan, China. 1 Named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to its phylogenetic proximity to the already known causative agent of severe acute respiratory syndrome (SARS) first identified in 2003, the virus spread quickly to other countries. 2 The arrival of coronavirus disease 2019 in Brazil in February 2020 represented a great challenge in establishing adequate strategies to mitigate the impact caused by the disease, as the country has continental dimensions and significant regional differences. One of these obstacles is the possibility of compromising access by children and adolescents with cancer to pediatric oncology centers, which is already constrained by the fact that these facilities are almost exclusively located in urban regions such as state capitals and regional economic centers. 3 Although Brazil has one of the world's largest and most complex publicly funded, free-at-the-point-of-care universal health system, the Sistema Único de Saúde (SUS), 4 the economic and social challenges faced by large segments of the population can increase the risk of exposure to SARS-CoV-2, as well as cause a worse prognosis. 5 Few studies have addressed the impact of COVID-19 on the pediatric population with cancer, and even fewer have been conducted with children from low-and middle-income countries (LMICs). 6, 7 It is already known that all age groups are susceptible to SARS-CoV-2. 8 In the oncology setting, Liang et al. suggest that adults with cancer have an increased risk of infection with this virus. 9 However, Boulad, de Rojas, and Ferrari and their respective coauthors believe that pediatric cancer patients, although managed as high risk, may be no more vulnerable to infection or morbidity resulting from SARS-CoV-2 than are other children. [10] [11] [12] Given this scenario, the present study describes the impact of COVID-19 on this population. Through a nationwide multicenter registry, 13 we identified factors related to worse prognosis in children with cancer, such as body mass index (BMI), age, and initial clinical presentation. In addition, we evaluated the mortality/fatality rate in comparison with the general pediatric population. During the 1-year period (from April 2020 to March 2021), pediatric patients (age 0-18 years) with cancer and infected by the SARS-CoV-2 virus seen at pediatric oncology centers were registered. All patients in this study were tested and had their confirmed diagnosis by reverse transcriptase-polymerase chain reaction (RT-PCR). Patients with suspected COVID-19 based on clinical and/or radiological criteria whose molecular diagnostic tests were negative were excluded from the analysis. Children and adolescents who died due to causes unrelated to COVID-19 were also excluded from the study. were used to compare Kaplan-Meier survival curves between two or more groups. Ethical approval to conduct this study has been granted by the Ethics Committee of HCPA. The legal guardians of all participating minors provided written informed consent in duplicate, keeping one copy of the consent form for themselves. One hundred seventy-nine pediatric patients were included ( Figure 1 ). We also observed that the group of patients whose initial severity was considered critical experienced worse outcomes when compared to the other groups (p < .001; Figure 2 ). Comparatively little data are available on the pediatric population with COVID-19 in developing countries. There is even less information about children with cancer infected with SARS-CoV-2 in these countries. The present study described the clinical presentation and course of these patients in a middle-income country, seeking to provide clues about possible risk factors for a less favorable prognosis. In the present national registration study, a high lethality rate was observed in and compare these data with other pediatric inflammatory diseases. The authors suggested that MIS-C differs from other known pediatric inflammatory entities. 18 To date, we are not aware of a study that sought to describe inflammatory markers in children with cancer who developed COVID-19. In our sample, there was no correlation between the evaluated markers and severity or prognosis. Data on prognosis and outcome of pediatric cancer patients infected with SARS-CoV-2 remain scarce. A study carried out with 523 adult patients with COVID-19 in four hospitals in Wuhan established an association of low BMI and protein levels with higher risk of death. In that study, patients with BMI under 20.5 kg/m 2 were more prevalent among ICU nonsurvivors than those with a normal BMI. 19 In addition, obesity and overweight were described as risk factors in a meta-analysis by Hussain et al. In 14 studies selected for quantitative analysis, BMI >25 was directly associated with higher mortality, as were factors such as advanced age (>70 years), severe comorbidities, and requiring advanced respiratory support. 20 Some studies in Brazil have addressed the impact of nutritional status on the survival of acute leukemias and found that low weight for age at diagnosis is associated with a worse prognosis due to a higher rate of recurrences. 21 In a cohort that analyzed obesity in lymphoblastic leukemia, the 5-year event-free survival in patients was significantly lower than that of the non-overweight/obesity patients. 22 In this context, we observed that pediatric cancer patients with a BMI below the value considered appropriate for their age were also significantly more likely to die acutely when infected with SARS-CoV-2. Likewise, the group of patients classified as overweight/obese had a worse prognosis than patients with adequate nutritional status. Considering these analyses, our data suggest that the nutritional situation may have an impact on the clinical response and prognosis related to SARS-CoV-2 acute infection. It can be observed that 49 (40.2%) patients of our sample (n = 122) received antiviral treatment, especially oseltamivir. Due to lack of evidence regarding effective treatments for COVID-19 in the first few months of pandemic, it is believed that some treatment centers appealed to these antivirals in off-label use. To the present day, oseltamivir is not recommended against SARS-CoV-2 infection. 23 Also, evidences of proven benefit from the use of corticosteroids was not clear until June 2020, when the preliminary data from the RECOVERY Trial was published. 24 Our study has some limitations, mostly inherent to the conduct of a multicenter registry in a country of continental dimensions with major regional differences. As the questionnaire was completed by local teams at each facility rather than centrally, some data required careful monitoring to ensure uniformity and consistency; despite our best efforts, some data could not be obtained for all patients. Another important point refers to the short follow-up period. We were able to identify acute repercussions such as hospitalizations and survival. Only through continuous monitoring of these patients will we be able to understand the long-term repercussions of infection in these children. In addition, it is possible that not all children diagnosed with COVID-19 in the period of interest entered the register or there was a variation in systematic screening between institutions, causing a selection bias and, consequently, leading to a higher proportion of most serious patients. It is also important to mention that due to the small number of events, results of a multivariable analysis could be biased and therefore has not been performed. 25, 26 Despite these, a very striking result is the case fatality rate in our sample. Unfortunately, it is similar to what was previously described by Montoya et al., who observed 10% of deaths in a pediatric cancer population with COVID-19 (ages ranging from 0 to 16) from six tertiary centers in Peru, 6 but very different from what was described in other pediatric studies. In a nationwide register-based study conducted in Brazil, it was found a rate of 0.7% of the deaths related to COVID-19 in the healthy pediatric population. 27 In a systematic review that evaluated 131 studies across 26 countries, the case fatality rate was less than 1%. 8 It shows that despite socioeconomic differences between highincome and low-income countries, the mortality rate of COVID-19 in healthy children is similar and very lower than those with cancer. In this context, the reasons why children with cancer in LMICs are at greater risk of developing severe forms of COVID-19 and progressing to death remain to be clarified. It is possible that immunosuppression associated with treatment or underlying disease plays a role, but the relationship between survival and BMI found in our study suggests that social issues leading to a more precarious nutritional status may be important in the origin of this result. With the continuity of the record, we hope to be able to better understand how variables related to the socioeconomic context can interfere in the prognosis, as well as to determine the longterm impact of SARS-CoV-2 infection in these children. A novel coronavirus outbreak of global health concern The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Assistencia ao cancer entre criancas e adolescentes: mapeamento dos fluxos origem-destino no Brasil Brazil's unified health system: the first 30 years and prospects for the future Desigualdade econômica e risco de infecção e morte por COVID-19 no Brasil COVID-19 in pediatric cancer patients in a resource-limited setting: national data from Peru Early impact of the COVID-19 pandemic on paediatric cancer care in Latin America COVID-19 in 7780 pediatric patients: a systematic review Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China COVID-19 in children with cancer in New York City COVID-19 infection in children and adolescents with cancer in Madrid Children with cancer in the time of COVID-19: an 8-week report from the six pediatric onco-hematology centers in Lombardia RECOV-Brasil: COVID-19 in Children Undergoing Cancer Treatment or HSCT in Brazil Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study The COVID-19 pandemic: a rapid global response for children with cancer from SIOP The risk and prognosis of COVID-19 infection in cancer patients: a systematic review and metaanalysis Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 Nutritional risk and therapy for severe and critical COVID-19 patients: a multicenter retrospective observational study Obesity and mortality of COVID-19. Meta-analysis Malnutrition as a prognostic factor in lymphoblastic leukaemia: a multivariate analysis Overweight as a prognostic factor in children with acute lymphoblastic leukemia Guidelines for the pharmacological treatment of COVID-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. Rev Bras Ter Intensiva Dexamethasone in hospitalized patients with COVID-19 Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy Importance of events per independent variable in proportional hazards regression analysis II Socio-economic inequalities and COVID-19 incidence and mortality in Brazilian children: a nationwide register-based study SARS-CoV-2 in children with cancer in Brazil: Results of a multicenter national registry. Pediatr Blood Cancer The authors thank the investigators from all participating centers across the country, as well as the Brazilian Society of Pediatric Oncol- The authors declare that there is no conflict of interest. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to information that could compromise the privacy of research participants.